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yield of the technique. That study showed that FDG PET contributed to the treatment of brain tumor patients who needed stereotactic biopsy. In 1995, Pirotte and colleagues [5, 6] reported on multiple studies of PETguided stereotactic brain biopsy. They described a technique allowing routine integration of PET scan data in the planning of stereotactic brain biopsy for patients who had undergone combined FDG PET and CTguided stereotactic biopsy. They integrated PET images into the planning for stereotactic biopsy procedures to direct the biopsy needle trajectory to hypermetabolic foci of intrinsic infiltrative brainstem lesions.
By integrating FDG PET in the planning of stereotactic brain biopsy, Goldman et al. [7] investigated whether the glucose meta bolism of gliomas is related to anaplasia and whether FDG PET depicts metabolic heterogeneity that parallels the histologic heterogeneity of gliomas. This early study showed that FDG uptake in gliomas is anatomically heterogeneous and regionally related to the presence of anaplasia. In 2013, Koethe et al. [8] reported that PET-guided biopsy with needle navigation facilitates the diagnosis of angiosarcoma in neurofibromatosis. In the latest development, PET/CTbased metabolic imaging has been integrated with standard MRIguided stereotactic biopsy. Zhao et al. [9] investigated the clinical value of intraoperative MRI coregistration combined with PET/CT for stereotactic brain biopsy. Compared with intraoperative MRI only, the combined treatment improves the diagnostic success rate without increasing complications [9] .
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Studies have been conducted to compare PET performed with 11 C-methionine (MET) and FDG for guidance of brain biopsy. Pirotte and colleagues [10, 11] compared the contributions of MET and FDG for PET-guided stereotactic biopsy of brain gliomas. PET images were analyzed to determine which radiotracer offered the best information for target definition. The study results showed that distributions of the highest MET and FDG uptake are similar in brain gliomas. Because MET provides a more sensitive signal, it is the molecule of choice for single-radiotracer PETguided neurosurgical procedures for glioma [10, 11] . In another study, Pirotte et al. [12] assessed the benefit of the technique in terms of target selection and diagnostic yield. Patients with newly diagnosed intrinsic infiltrative brainstem lesions underwent PETguided stereotactic biopsy. A single biopsy target was selected in the area of highest PET tracer uptake. Use of PET guidance improved the target selection and allowed tumor diagnosis in all trajectories. The PET-guided trajectories had higher diagnostic yield than those guided by MRI alone and allowed reduction of sampling to a single trajectory.
PET guidance improves the diagnostic yield of stereotactic biopsy sampling, allows the clinician to reduce the number of sampling procedures, and leads to a reassessment of the utility of and indications for stereotactic biopsy in children with intrinsic infiltrative brainstem lesions. Kawai et al. [13] described a patient with germinoma in the basal ganglia that had nonspecific clinical and radiologic findings and found MET PET useful for locating the optimal biopsy target and monitoring treatment efficacy. In a study by Goldman et al. [14] , local histologic characteristics were used to confirm the regional uptake of FDG and MET in patients with high-grade glioma diagnosed during PET-guided stereotactic biopsy. Both MET PET and FDG PET were useful for in vivo evaluation of the metabolic heterogeneity of human gliomas. These results underline the complementary role of FDG and MET for the study of brain tumors and favor the use of these agents for stereotactic PET guidance of diagnostic procedures.
Other radiotracers have been used for the guidance of brain biopsies. Go et al. [15] used spectroscopic MRI and l-1-11 C-tyrosine PET to localize cerebral gliomas for biopsy. Hara et al. [16] used 18 F-choline and 11 C-choline for PET-guided stereotactic biopsy sampling of gliomas. The PET scans of gliomas in which 18 F-and 11 C-choline were used to guide the approach to the most malignant areas for stereotactic sampling. Amino acid 18 Ffluoroethyltyrosine PET (FET PET) has been used to identify metabolically active tumor tissue and to differentiate it from therapy-associated changes. A study by Misch et al. [17] showed that the indications for FET PET were visualization of metabolically active malignant tissue within anatomically defined lesions or previously treated tumors and assessment of their extent ( Fig.  1 ). FET PET was helpful for target selection and was integrated into surgical guidance. FET PET image-guided surgical targeting yielded histologic diagnoses with appropriate specificity and high sensitivity in the care of pediatric brain tumor patients.
Lopez et al. [18] correlated the histopathologic criteria of biopsy sites with PET uptake values. They analyzed the diagnostic value of PET by comparing the FET PET findings in patients with newly diagnosed brain lesions with the histologic findings obtained from stereotactic serial biopsy. FET PET allowed differentiation of high-grade glioma from low-grade glioma. In a 2016 study, Kondo et al. [19] found that anti- 18 Ffluciclovine PET/CT can delineate glioma spread that is undetectable at contrast-enhanced T1-weighted MRI and can be used to guide glioma biopsy.
Pafundi et al. [20] compared 18 F-dihydroxyphenylalanine (DOPA) PET with conventional MRI for neurosurgical biopsy targeting, resection planning, and radiotherapeutic target volume delineation. The study showed that regions of higher-grade and higher-density disease were accurately identified with DOPA standardized uptake values in patients with astrocytomas and that DOPA PET was useful for guiding stereotactic biopsy selection. Price et al. [21] compared regional variations in the uptake of 18 Ffluorothymidine (FLT) PET images with measures of cellular proliferation from biopsy specimens obtained at image-guided brain biopsies. Patients with a supratentorial glioma that required image-guided brain biopsy underwent preoperative imaging with dynamic PET after administration of FLT. Maps of the FLT irreversible uptake rate and the standardized uptake value were calculated. These maps were coregistered to a gadolinium-enhanced T1-weighted spoiled gradient-echo MR image that was used for biopsy guidance. The study showed that FLT PET was a useful marker of cellular proliferation that correlates with regional variation in cellular proliferation.
Because MRI alone has limitations in target selection for biopsy or resection in patients with newly diagnosed or pretreated brain tumors, the combination of PET and MRI or in vivo MR spectroscopy (MRS) allows noninvasive imaging of cellular meta bolism relevant to proliferation and can depict regions of more highly active tumor. Masada et al. [22] used coregistered PET and MR images to determine the biopsy target and performed brain biopsy guided by a stereotactically inserted tube. The coregistered PET and MR images depicted the most active region of the brain tumor.
Guo et al. [23] assessed the value and feasibility of PET/MRI fusion technology for delineating tumor boundaries and positioning biopsy targets of gliomas to facilitate the diagnosis and treatment of gliomas. They used MRI, FDG PET, and fluoroethylcholine (FECH) PET in the study. With regard to patients who underwent both biopsy and tumor resection, the pathologic diagnosis of the specimen obtained from the PET-guided biopsy was consistent with that of subsequently resected tissue. PET-MRI fusion accurately delineated the tumor boundary and sensitively targeted the region of high proliferation or metabolism.
Grech-Sollars et al. [24] integrated presurgical PET and MRS with intraoperative neuronavigation to guide surgical biopsy and tumor sampling of brain gliomas to improve intraoperative tumortissue characterization and imaging biomarker validation. They developed an intraoperative neuronavigation tool as part of the study with the intention of sampling high-choline tumor components identified with multivoxel MRS and 18 Fmethylcholine PET/CT. Spatially coregistered PET and MRS data were integrated into structural datasets and loaded into an intraoperative neuronavigation system. Regions of high and low uptake of choline and metabolites were represented as color-coded, hollow spheres for targeted stereotactic biopsy and tumor sampling. These PET and MRI data were combined for the surgeon in neuronavigation systems. This multimodality imaging method enabled neurosurgeons to sample tumor regions based on physiologic and molecular imaging markers.
Bone
FDG PET and 99m Tc-methylene diphosphonate bone scintigraphy are useful imag-
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ing modalities for detecting skeletal metastases. PET is believed to be more specific than bone scintigraphy for detecting malignancy [25] . Pezeshk et al. [25] investigated the value of PET compared with bone scintigraphy for directing biopsies in patients with suspected metastatic bone lesions. The results of their study support the use of PET to effectively direct bone biopsies to confirm the presence of metastatic neoplasms. The results also suggest that PET may incrementally improve the diagnostic yield over that of bone scintigraphy.
Other studies [26] [27] [28] [29] have shown FDG PET/CT useful for bone and softtissue biopsy. Werner et al. [26] reported a case of FDG PET/CT-guided biopsy of bone metastases. Purandare et al. [28] studied whether the metabolic information provided by a previous PET/CT scan can add valuable information and be of incremental benefit during the performance of image-guided biopsies. The biopsy sites included bone, lung, lymph nodes, and softtissue masses. PET/CT data were coregistered with intraprocedural CT images and were used to guide needle placement in the viable portion of a lesion, increasing the chances of achieving a definitive diagnosis. This approach offered a substantial incremental benefit in the performance of image-guided biopsies.
Maybody et al. [29] reported results on a patient with a clinical diagnosis of tumorinduced osteomalacia in whom the culprit tumor was localized with 68 Ga-tetraazacyclododecanetetraacetic acid-Phe1-Tyr3-octreotide PET/CT and MRI, and the biopsy was performed under PET/CT guidance. Guo et al. [30] evaluated the safety and efficacy of FDG PET/CT for guiding biopsy of bone metastases in patients with advanced lung cancer. PET/CTguided percutaneous core biopsies were performed for patients with suspected lung cancer and FDGavid bone lesions after wholebody FDG PET/CT. PET/CTguided percutaneous biopsy of FDGavid bone metastases is an effective and safe method that has a high diagnostic success rate in the evaluation of hypermetabolic bone lesions in patients with suspected advanced lung cancer.
Lymph Nodes
FDG PET plays an important role in lymph node biopsies. Kim et al.
[31] designed a study to determine whether preoperative FDG PET integrated with CT can be used as a guide for axillary node dissection and sentinel lymph node biopsy (SLNB) in breast cancer patients, reducing the number of unnecessary SLNBs and thus enhancing the identification rates of sentinel nodes and the accuracy of SLNB. Purandare et al. [28] studied whether the metabolic information obtained in a previous PET/CT scan can add valuable information and an incremental benefit during imageguided biopsies. The patients' FDG PET/CT findings were available before biopsy. Biopsies were performed with standard techniques only after the needle tip was confirmed to be in the portion of the lesion corresponding to the hypermetabolic area on PET images. This was achieved by visual coregistration and by use of software registration algorithms that registered the intraprocedural CT images with the preselected PET/CT data. The study showed that PET/CT data coregistered with intraprocedural CT images could guide needle placement in the viable portion of the lesion, increasing the chances of achieving a definitive diagnosis. This approach added significant incremental benefit to performing image guided biopsies. Challa et al.
[32] studied the role of FDG PET/CT in the evaluation of axillary lymph node involvement and compared the results with those of SLNB. Their study showed that FDG PET/CT has low sensitivity but high specificity in the evaluation of axillary lymph node involvement in patients with breast cancer.
PET has been used in various lymph node biopsies. Siepel et al. [33] reported on a study of targeted mediastinoscopic lymph node biopsy performed with 3D FDG PET/CT videos. The feasibility and potential value of 3D FDG PET/CT videos were investigated to improve the accuracy of targeted lymph node biopsy during mediastinoscopy. PET/CT images were rendered in 3D volumes with multiplanar reconstructions and maximum intensity projections and were reviewed in 3D flythrough and flyaround videos. The results showed that use of PET/CT videos may reduce the frequency of falsenegative mediastinoscopic findings and improve the staging of lung cancer. The study showed that 3D FDG PET/CT may be a promising tool for further implementation of image-guided surgery. Györke et al.
[34] described a case of lymphoma in which an occult lesion localization method was used for radioguided biopsy of a chemoresistant lymph node detected with interim FDG PET/CT. Biopsy of the metabolically active, nonpalpable lymph node was performed with ultrasound guid-ance ( Fig. 2) . Juweid et al. [35] reported on the potential use of the interim FDG standardized uptake value for determining the need for a residual mass biopsy after dosedense immunochemotherapy for advanced diffuse large B-cell lymphoma.
Breast
The use of PET in the care of patients with breast cancer has been limited by the lower levels of FDG uptake in some breast malignancies than in other cancers, the small size of many breast cancers, and the need for biopsy under PET guidance. High-resolution breast PET, or positron emission mammography (PEM), with biopsy guidance software is a new direction. Kalinyak et al. [36] reported the results of a prospective multicenter study designed to test the efficacy and safety of PEM biopsy guidance software for women with FDGavid breast lesions worrisome for malignancy. The intervention chosen was vacuumassisted core biopsy. The study showed that high-resolution PEMguided breast biopsy is safe and effective for the sampling of PETvisualized breast lesions. Raylman et al.
[37] described the design of a PEM-PET breast imaging and biopsy system. The PEM-PET scanner consists of two sets of rotating planar detector heads. PET images are acquired to detect suspicious focal uptake of the radiotracer and guide biopsy of the area. The PEM-PET system may be a new tool for the detection and biopsy of breast cancer in the future.
Chest
Once lung cancer is discovered, accurate staging at baseline is imperative to maximize patient benefit and costeffective use of health care resources. Although CT remains a powerful tool for the staging of lung cancer, advances in other imaging modalities, specifically PET/CT and MRI, can improve the baseline staging over that of CT alone and can allow more rapid and accurate assessment of the treatment response [38] . FDG PET has been considered a "metabolic biopsy" [39] tool in the evaluation of nonlung lesions with indeterminate biopsy results. Niida et al. [40] reported a case in which pulmonary intravascular lymphoma was diagnosed with FDG PET-guided transbronchial lung biopsy. Purandare et al. [28] found that lung biopsies were performed only after the needle tip was confirmed to be in the portion of the lesion corresponding to the hypermetabolic area seen on PET images. This
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was achieved by visual coregistration and by the use of software registration algorithms that registered the intraprocedural CT images with the preselected PET/CT data. Their study showed that PET/CT data coregistered with intraprocedural CT images could guide needle placement in the viable portion of the lesion and thus increase the chances of achieving a definitive diagnosis. Collins et al. [41] reported that CTguided, fineneedle aspiration (FNA) biopsies performed with FDG PET scans of pulmonary lesions contributed substantially to the management and treatment of pulmonary disease.
İntepe et al.
[42] compared the results of transthoracic needle biopsies performed with and without FDG PET/CT. Their study showed that using FDG PET/CT to guide transthoracic biopsy increases the rate of accurate diagnosis ( Fig. 3 ). Lin [43] reported a case in which FDG PET/CT was used for biopsy guidance in a patient with Erdheim-Chester disease. The PET/CT was important in identifying an area for biopsy and for visualizing bone involvement. Yokoyama et al.
[44] compared the results of CT-guided, percutaneous biopsy with and without registration of previous PET/CT images in the diagnosis of mediastinal tumors. The study showed that PET/CT is not typically needed because CT-guided percutaneous biopsy can yield a precise diagnosis of most mediastinal tumors. It also showed that PET/CTguided biopsy had no special diagnostic advantages.
PET has also been used as a noninvasive imaging modality for the staging of esophageal cancer [45] . Mizugaki et al.
[46] evaluated the combination of transbronchial biopsy and endobronchial sonography with a guide sheath (EBUS-GS) and FDG PET for the diagnosis of small peripheral pulmonary lesions. The combination of transbronchial biopsy with EBUS-GS and FDG PET is useful for the diagnosis of these small lesions. Combined FDG PET/CT-and CTguided biopsy has also been used for diagnosing recurrence of esophageal cancer [47] .
Head and Neck
In the assessment of locally recurrent and metastatic head and neck neoplasia, FNA biopsy and FDG PET are highly sensitive for identifying tumors in patients with clinically suspected recurrence and locally metastatic disease [48] . FNA biopsy can yield confirmatory evidence of disease in a clinically suspicious abnormality with nonspecific FDG PET results. Kovács et al. [49] re-ported that PET in combination with SLNB reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. Compared with CT, PET in combination with lymphoscintigraphy-guided SLNB considerably reduces the number of extensive neck dissections in patients with oral and oropharyngeal squamous cell carcinoma. Reinbacher et al. [50] described a method of 3D image-guided biopsy of orbital tumors using a combined technique of hardware fusion between FDG PET, MRI, and CT. The method allows minimally invasive biopsy even of deep intraconal lesions and allows the surgeon to spare critical anatomic structures (Fig. 4 ).
Abdomen and Pelvis
PET has a major role in the diagnosis and staging of abdominal and pelvic diseases, especially liver and prostate cancer. Tatli et al. [51] developed a technique for guiding percutaneous biopsies of abdominal masses using a PET/CT scanner. After completion of the PET/CT scan, with the patient remaining on the table, a onetableposition PET/CT scan was obtained with a radiopaque grid in place, and the biopsy procedure was planned. A biopsy needle was then placed into the mass by use of a one-table-position CT scan registered to the planning PET scan. Masses were sampled after confirmation of accurate positioning of the needle tip with a final, onetableposition PET/CT scan. The study results suggested that abdominal masses can be successfully biopsied with a PET/CT scanner.
Tatli et al. [52] also studied the feasibility of performing combined PET/CTguided biopsy of abdominal masses using previously acquired PET/CT images registered with intraprocedural CT images. PET/CTguided abdominal biopsy using previous PET/CT images registered with intraprocedural CT scans was helpful for biopsy sampling of FDGavid masses not seen sufficiently with unenhanced CT.
Aparici and Win [53] reported the case of a patient for whom FDG PET/CT was used to perform biopsy of a mesenteric mass. Real-time intraprocedural PET-guided biopsy of a new mesenteric mass revealed Bcl2positive, poorly defined lymphoid follicles compatible with follicular lymphoma (Fig.  5 ). PET/CTguided biopsy allowed early histologic diagnosis and staging before morphologic changes were evident by allowing sampling of the metabolically active part of the lesion.
Liver
Shao et al. [54] investigated the accuracy of PET/CT and ultrasoundguided biopsy for the diagnosis of liver carcinomas. Before surgery, patients underwent PET/CT assessment, an ultrasound examination, and ultrasoundguided biopsy of liver tissue. The combined use of PET/CT, ultrasound assessment, and ultrasound-guided biopsy can improve the diagnosis of liver cancer. FNA biopsy is a well-described diagnostic method for evaluation of hepatic lesions. The FDG PET scan, combined with FNA biopsy, can provide reliable diagnostic information and assist in the guidance of oncologic patient care [55] . Yu and Sheng [56] reported a case in which liver tuberculosis presented as an uncommon cause of pyrexia of unknown origin and in which PET/CT helped to identify the correct site for biopsy. Ewertsen et al. [57] reported that the use of fusion-guided sonography facilitated conclusive diagnosis regarding lesions in the liver seen at CT, MRI, or PET/CT. The study showed an increase in characterization of liver lesions with fusion-guided ultrasound compared with conventional Bmode ultrasound. Imperiale et al. [58] reported the results of simultaneous 18 Ffluorodihydroxyphenylalanine PET/CTguided biopsy in a patient with hepatic metastatic evolution of a welldifferentiated ileal neuroendocrine tumor. The study showed that PET/CTguided biopsy is useful for confirming the metabolic findings when conventional imaging does not show morphologic abnormalities (Fig. 6 ).
Prostate
PET can depict metabolic and functional information about prostate cancer. Various PET agents were developed or are under development for prostate cancer detection. PET with new molecular imaging radiotracers, such as choline, prostatespecific membrane antigen, and fluciclovine, has had promising results in the detection and localization of prostate cancer in humans [59, 60] . For patients with previous negative biopsy results but elevated prostatespecific antigen (PSA) levels, PETguided biopsy can have an important role in the management of prostate cancer.
Fei and colleagues [61] [62] [63] [64] developed an approach to PET molecular image-directed 3D ultrasound-guided biopsy. The components of the targeted biopsy system are passive mechanical components for guiding, tracking, and stabilizing the position of a commercially available transrectal ultrasound probe; soft-
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ware for acquiring and reconstructing a series of real-time 2D transrectal ultrasound image slices into a 3D image volume of the prostate; and software that segments the prostate gland in the 3D transrectal ultrasound image volume and then displays a 3D model to guide a biopsy needle to the suspicious target lesions in three dimensions. The system allows real-time tracking and recording of the 3D position of the biopsy sites as a physician manipulates the ultrasound transducer. An offline workstation system is used to register and fuse PET/CT and ultrasound images.
The clinical work flow for PET/CTdirected, 3D ultrasound-guided biopsy of the prostate includes the following steps. First, before undergoing the targeted biopsy, the patient undergoes PET/CT as part of his evaluation. The anatomic CT images are registered with the PET images for improved localization of the prostate and suspicious lesions. Second, the patient undergoes 3D ultrasound (prebiopsy image) before the actual biopsy appointment. This planning scan may be obtained at any time before the biopsy and even on the same day as the PET/CT examination. Third, the PET/CT and prebiopsy ultrasound images are registered offline before biopsy. Fourth, another 3D ultrasound image volume is acquired immediately before the biopsy planning. These intrabiopsy ultrasound images are registered with the prebiopsy ultrasound image volume. As the prebiopsy ultrasound image volume was registered with the PET/CT volumes, in turn the PET/CT image is registered with the intrabiopsy ultrasound image volume for tumor targeting. Threedimensional visualization tools are then used to guide the biopsy needle to a suspicious lesion. Fifth, the position of the needle tip is recorded on real-time ultrasound images during the biopsy procedure. The location information on biopsy cores is saved and can be restored in a rebiopsy procedure if necessary. This allows the physician to rebiopsy the same area and monitor the potential progression of or treatment effects on a lesion. The location information on the biopsy cores can also be used to guide an additional biopsy to different locations if the original biopsy results were negative.
PET with 11 C-choline and 18 F-choline has been used to guide prostate biopsies. Freesmeyer et al. [65] reported a case in which atypical cancer recurrence in the right distal lower leg was suspected at FECH PET/CT of a patient with a history of prostate cancer and an increased PSA level. A PETultrasound fusion technique was used to localize the tu-mor and perform a biopsy, which led to a final diagnosis of peripheral schwannoma. Garcia-Bennett et al. [66] reported a case of 18 Fcholine PET/CT detection of a needle track recurrence after transrectal prostate biopsy.
Kwee and DeGrado [67] reported a case of prostate biopsy guided by 18 Ffluorocholine PET in a patient with persistently elevated PSA levels. In a study by Igerc et al. [68] , patients with persistently elevated PSA levels and negative prostate biopsy results were evaluated with 18 Fcholine PET/CT to delineate prostate cancer and guide repeat prostate biopsy. After PET/CT, all patients underwent a repeat prostate biopsy, and in the cases in which focal or multifocal uptake was found, the biopsy was guided by the results of the examination. The results of the study show that 18 F-choline cannot be generally recommended for localizing primary prostate cancers.
Takei et al. [69] , however, reported a case of multimodality multiparametric 11 C-choline PET/MRI for biopsy targeting in previously biopsynegative primary prostate cancer. For targeting rebiopsy, the patient underwent 11 Ccholine PET/CT and subsequent PET/MRI. Both the high uptake at PET and the abnormal findings at MRI were strong evidence of prostate cancer at the ventral periphery of the right apex (Fig. 7) . This location is sometimes not covered by routine sextant biopsy, and the subsequent targeted rebiopsy was positive for prostate cancer. This case indicates the potential role of PET/MRI for identifying primary prostate cancer because of its high soft-tissue contrast and the possibility of a multimodality approach.
PET with other tracers has also been used to direct prostate biopsy. Jadvar et al. [70] reported the case of a patient with prostate cancer who had an elevated PSA level and had undergone a previous standard transrectal ultrasound biopsy with negative results and then underwent clinical 3-T multiparametric MRI and PET/CT with the cellular proliferation radiotracer 18 F-labeled 2′fluoro 5-methyl-1-β-d-arabinofuranosyluracil (FMAU). PET/CT and multiparametric MR images were fused with transrectal ultrasound images for hybrid image-based targeting of the biopsy needle. FMAU PET/CT was helpful in localizing the nonstandard biopsy sites that histopathologic analysis revealed to be tumor deposits.
Muscles
The development of FDG PET/CT has made it possible to identify many unsuspect-ed lesions, such as isolated intramuscular metastases, because it depicts abnormal metabolic activity at an early stage, even without clinical symptoms or morphologic changes [71] . PET/CT has been used to localize the primary lesion, identify a site to biopsy, and evaluate metastatic lesions that require follow-up biopsy [72] (Fig. 8 ). Mallarajapatna et al. [71] described a technique in which fused PET/CT was used to guide the percutaneous biopsy needle for sampling of isolated intramuscular metastatic lesions in a patient with intramuscular metastases identified only with PET/CT, not CT or ultrasound, and were clinically occult. Not all malignant tumors have hypermetabolic activity at PET, and many benign lesions and physiologic processes cause increased FDG uptake. Knowledge of these issues is important in reviewing PET/CT images and directing subsequent musculoskeletal biopsies [72] .
Sarcoma
For soft-tissue masses, FDG PET has been found to be useful in identifying malignancy and variations in grade. MRI has been the most useful tool in the anatomic definition of soft-tissue sarcoma, although there remains the problem of defining the lesions as benign or malignant. Hain et al. [73] assessed the use of FDG PET with or without coregistered MR images to indicate the most appropriate biopsy site. All patients underwent MRI and FDG PET, and the two images were coregistered. A biopsy site that was the most likely to be malignant was defined on the PET scan. Patients underwent an initial biopsy and then complete resection of the mass. The histologic results from the mass were compared with those from the biopsy specimen obtained from the site suggested by the PET findings. The study showed that FDG PET can be used to appropriately direct biopsy of soft-tissue sarcoma and potentially lead to CT-or MRI-directed outpatient biopsy before definitive treatment.
Specimen
With PETguided biopsy, the in vivo imaging findings can be directly correlated with the histologic results of biopsy specimens. Fanchon and colleagues [74, 75] developed a procedure for accurate determination of PET radiotracer concentration with high spatial accuracy in situ by performing quantitative autoradiography of biopsy specimens extracted under PET/CT guidance (Fig. 9 ). The biopsy sites were determined with PET/CT
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images obtained in the operating room. Additional CT scans were acquired with the needles in place to confirm correct needle placement. Autoradiography was used to quantify the activities of biopsy specimens obtained under FDG PET guidance. The PET-guided approach and quantification method helped verify biopsy adequacy through a comparison of specimen activity and that expected from the PET image.
Conclusion
PET-directed biopsy has an increasing role in the diagnosis and staging of various diseases. Molecular image-guided biopsy approaches have great potential to increase the detection rate and improve diagnostic accuracy and therefore can have immediate impact on treatment decisions and patient care. 
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